Clinical trials: Placebo-Post
Non-alcoholic Steatohepatitis
Investigate Safety, Tolerability, PK/PK of J2H 1702 in Healthy Males
1. Research Purpose: To evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic properties of J2H-1702 (a candidate for treatment of non-alcoholic steatohepatitis) in healthy men. 2.
- Trial name
- NCT06308861
- Testing
- Single administration Amg dose Group, Single administration Bmg dose Group, Single administration Cmg dose Group
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- J2H Biotech
Type 2 Diabetes
Single Ascending Dose Study With Healthy Male Volunteers and Type II Diabetic Patients
The purpose of this study is to assess safety and tolerability of AZD6714 after single ascending oral doses in healthy male subjects and type 2 diabetic patients.
- Trial name
- NCT00886366
- Testing
- AZD6714
- Where
- Sweden
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Multiple Oral Doses of BIBR 1048 MS Solution in Healthy Volunteers
To assess safety, pharmacokinetics and the effect of BIBR 1048 MS on coagulation parameters.
- Trial name
- NCT02170831
- Testing
- BIBR 1048 MS low, BIBR 1048 MS medium 1, BIBR 1048 MS medium 2
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Myelofibrosis, Primary Myelofibrosis
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving…
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
- Trial name
- NCT04551053
- Testing
- parsaclisib, ruxolitinib
- Where
- 177 sites in United States, Austria and 17 more
- Volunteers
- 177 people
- Sponsor
- Incyte Corporation
Post Herpetic Neuralgia
Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia
The purpose of this study is to investigate whether NXN-462, a selective nNOS inhibitor, is effective in reducing pain levels in patients with post-herpetic neuralgia.
- Trial name
- NCT01748877
- Testing
- NXN-462
- Where
- 25 sites in United States, Canada
- Volunteers
- 188 people
- Sponsor
- NeurAxon Inc.
Pulmonary Disease, Chronic Obstructive
A Study To Determine Effects Of Fluticasone Propionate On Sputum Neutrophils After Inhaled Lipopolysaccharide Challenge In Volunteers
Study to assess effect of Fluticasone Propionate on acute lung inflammation following inhaled lipopolysaccharide (LPS) challenge. Study will be conducted in healthy volunteers.
- Trial name
- NCT01364519
- Testing
- Fluticasone Propionate
- Where
- 2 sites in United Kingdom
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Safety, Tolerability and Pharmacodynamics of BIIX 1 XX in Healthy Young Male Volunteers
The objective of the present study is to obtain information about the safety and tolerability of BIIX 1 XX, to determine the pharmacologically active dose (range) by performing a methacholine challenge test and to obtain…
- Trial name
- NCT02199873
- Testing
- BIIX 1 XX - single rising dose
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Tooth; Lesion, White Spot Lesions
Remineralisation of White Spot Lesions by Elmex® gelée in Post-orthodontic Patients
The aim of this study is to monitor the effect of intraoral topical high fluoride application on the development of white spot lesions (WSL) after orthodontic treatment with multibracket appliances and to compare it to a placebo.
- Trial name
- NCT01329731
- Testing
- elmex® gelée
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Gaba International AG
Heart Failure, Heart Decompensation
A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute…
- Trial name
- COMPOSE EARLY (NCT01064037)
- Testing
- Cinaciguat (BAY58-2667)
- Where
- 70 sites in United States, Canada and 14 more
- Volunteers
- 62 people
- Sponsor
- Bayer
Healthy Volunteers
Study to Investigate the Influence of CKD-519 on 24-h Ambulatory Blood Pressure in Healthy Adult Volunteers
The purpose of this study is to determine influence of CKD-519 on 24-h ambulatory blood pressure after oral administration in healthy adult volunteers.
- Trial name
- NCT02916901
- Testing
- CKD-519 200mg
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Osteoporosis
CR9112792, a Follow-up of Study CR9108963
The purpose of this study is to determine whether bone mineral density has increased in a subgroup of postmenopausal osteoporotic women from study CR9108963, between 6 and 12 months following cessation of ronacaleret therapy.
- Trial name
- NCT00891553
- Testing
- DXA
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 171 people
- Sponsor
- GlaxoSmithKline
Volunteers, Healthy
A Study to Evaluate Plasma Gelsolin in Healthy Volunteers
Study BTI-101 is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation, parallel design study to evaluate the safety, tolerability, and pharmacokinetics of IV rhu-pGSN or saline placebo administered as 5 doses…
- Trial name
- NCT05789745
- Testing
- Recombinant human plasma gelsolin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- BioAegis Therapeutics Inc.
Ischemia-reperfusion Injury, Kidney Transplant; Complications
A Trial to Assess Efficacy and Safety of ex Vivo Allograft Admin of iCM012 Solution 2 mg/ml to Improve Its Function in Recipients of DCD Kidneys
Randomized (1:1), placebo controlled, double blind efficacy trial. 200 patients will be followed up for 12 months post transplantation.
- Trial name
- NCT06582485
- Testing
- iCM012 solution 2 mg/mL
- Volunteers
- 200 people
- Sponsor
- iCoat Medical AB
Type II Diabetes
Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes
The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Insulin
- Trial name
- NCT00856908
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Healthy
AZD1305 Single and Multiple Ascending Dose Study in Healthy Japanese and Caucasian Subjects
This is a phase I, single-blind, randomized, placebo-controlled single and repeated ascending dose study to assess the safety, tolerability and pharmacokinetics with oral doses of AZD1305 extended-release capsules in healthy male…
- Trial name
- JMAD (NCT00935025)
- Testing
- AZD1305
- Where
- 2 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteer
Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects
The study is designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of AZD1722 in healthy Japanese subjects at increasing doses given for 7 days in order to allow for including Japanese subjects in…
- Trial name
- NCT02176252
- Testing
- AZD1722
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Ardelyx
Autoimmune Diseases, Multiple Sclerosis
First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641
A Phase I First-in-Human, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate Safety, Tolerability, and Pharmacokinetics after Single and Multiple Oral Dose of LPX-TI641.
- Trial name
- NCT05853835
- Testing
- LPX-TI641
- Where
- 2 sites in United States, Jordan
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- LAPIX Therapeutics Inc.
Post-Operative Pain
Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injections for Post-Operative Pain Following Colorectal Surgery
The purpose of this Phase 2 study is to evaluate the efficacy and safety of an analgesic drug candidate, VVZ-149 Injections. The study is designed as randomized, double-blind, parallel, placebo-controlled study.
- Trial name
- NCT02489526
- Testing
- VVZ-149 Injections
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Vivozon, Inc.
Diffuse Large B-cell Lymphoma
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients had achieved complete response with first-line rituximab-chemotherapy
- Trial name
- PILLAR2 (NCT00790036)
- Testing
- Everolimus
- Where
- 202 sites in United States, Argentina and 32 more
- Volunteers
- 742 people
- Sponsor
- Novartis Pharmaceuticals
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection
Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving muscle function (metabolism) following moderate exercise in subjects with fatigue-Predominant Post-Acute…
- Trial name
- NCT05152849
- Testing
- AXA1125
- Where
- United Kingdom
- Volunteers
- 41 people
- Sponsor
- Axcella Health, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.